Indication
Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Medicine details
- Medicine name:
- lebrikizumab (Ebglyss)
- SMC ID:
- SMC2707
- Pharmaceutical company
- Almirall Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 11 November 2024
- SMC meeting date:
- 01 October 2024
- Patient group submission deadline:
- 02 September 2024